title: In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
abstract: OBJECTIVE
  This study aimed to investigate the predictive value of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for chemosensitivity test in ascites.
  
  
  METHODS
  The relationship of the in vitro sensitivity results and the clinicopathological characteristics, objective response rates (ORRs) of chemotherapy, and time to progression (TTP) were retrospectively analyzed in 120 epithelial ovarian cancer (EOC) patients. The clinical response criterion was based on the Response Evaluation Criteria in Solid Tumors (RECIST) standard. The log-rank test and Kaplan-Meier curve were used to estimate TTP.
  
  
  RESULTS
  MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0.01 and p < 0.01, respectively) and type I (p = 0.03, p = 0.02, respectively) EOC. p53 positive expression and Ki67 high expression were associated with high PTX (p = 0.01 and p < 0.01, respectively) and CBDCA (p = 0.03 and p < 0.01, respectively) sensitivity. Ki67 weak positive immunostaining was associated with topotecan (p < 0.01), gemcitabine (p < 0.01), and doxorubicin (p < 0.01) resistance. Chemosensitivity to CBDCA/PTX was associated with the ORR ofneo-adjuvant (p = 0.03) and adjuvant (p = 0.02) chemotherapy. The MTT assay results of ascites were consistent with the clinical response (p = 0.04) and TTP (p = 0.04) in patients with platinum-resistant relapse EOC tumors.
  
  
  CONCLUSIONS
  Evaluation of the chemosensitivity of ascites in EOC by MTT can aid the establishment of individualized clinical chemotherapeutic plans for platinum-resistant relapse patients.
authors.affiliation: Department of Chemotherapy, Jiangsu Institute of Cancer Research, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.affiliation: Medical School of Yangzhou University, Yangzhou, China.
authors.forename: H
authors.initials: H
authors.lastname: Dai
authors.affiliation: Nanjing Medical University, Nanjing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Pathology, Jiangsu Hospital of Integrated Traditional and Western Medicine, Nanjing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Nanjing Medical University, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Chemotherapy, Jiangsu Institute of Cancer Research, Nanjing, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Qian
authors.affiliation: Nanjing Medical University, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology / Q000473:pathology; D016190:Carboplatin / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D004396:Coloring Agents; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D004354:Drug Screening Assays, Antitumor; D015251:Epirubicin / Q000627:therapeutic use*; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D017239:Paclitaxel / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D004396:Coloring Agents; D019394:Ki-67 Antigen; D013778:Tetrazolium Salts; D013844:Thiazoles; D016159:Tumor Suppressor Protein p53; D003841:Deoxycytidine; D015251:Epirubicin; D005047:Etoposide; D016190:Carboplatin; C022616:thiazolyl blue; D017239:Paclitaxel; D005472:Fluorouracil; D000093542:Gemcitabine